公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
---|---|---|---|---|---|---|
2019 | ALK resistance mutations and efficacy of lorlatinib in advanced anaplastic lymphoma kinase-positive non–small-cell lung cancer | Shaw A.T.; Solomon B.J.; Besse B.; Bauer T.M.; CHIA-CHI LIN ; Soo R.A.; Riely G.J.; Ignatius Ou S.-H.; Clancy J.S.; Li S.; Abbattista A.; Thurm H.; Satouchi M.; Camidge D.R.; Kao S.; Chiari R.; Gadgeel S.M.; Felip E.; Martini J.-F. | Journal of Clinical Oncology | 284 | 208 | |
2020 | Asian Thoracic Oncology Research Group Expert Consensus Statement on Optimal Management of Stage III NSCLC | Tan W.L.; Chua K.L.M.; CHIA-CHI LIN ; Lee V.H.F.; Tho L.M.; Chan A.W.; Ho G.F.; Reungwetwattana T.; YCHIH-HSIN YANG ; Kim D.-W.; Soo R.A.; Ahn Y.C.; Onishi H.; Ahn M.-J.; Mok T.S.K.; Tan D.S.W.; Yang F. | Journal of Thoracic Oncology | 33 | 30 | |
2021 | Efficacy and Safety of S-1 Compared With Docetaxel in Elderly Patients With Advanced NSCLC Previously Treated With Platinum-Based Chemotherapy: A Subgroup Analysis of the EAST-LC Trial | CHIH-HSIN YANG ; Mok T.S.K.; Lu S.; Nakagawa K.; Yamamoto N.; Shi Y.-K.; Zhang L.; Soo R.A.; Morita S.; Tamura T. | JTO Clinical and Research Reports | 0 | 0 | |
2018 | Enhancer remodeling and MicroRNA alterations are associated with acquired resistance to ALK inhibitors | Yun M.R.; Lim S.M.; Kim S.-K.; Choi H.M.; Pyo K.-H.; Kim S.K.; Lee J.M.; Lee Y.W.; Choi J.W.; Kim H.R.; Hong M.H.; Haam K.; Huh N.; Kim J.-H.; Kim Y.S.; Shim H.S.; Soo R.A.; JIN-YUAN SHIH ; Chih-Hsin CHIH-HSIN YANG ; Kim M.; Cho B.C. | Cancer Research | 30 | 27 | |
2020 | Impact of lorlatinib on patient-reported outcomes in patients with advanced ALK-positive or ROS1-positive non-small cell lung cancer | Peters S.; Shaw A.T.; Besse B.; Felip E.; Solomon B.J.; Soo R.A.; Bearz A.; Gadgeel S.M.; CHIA-CHI LIN ; Kao S.; Seto T.; Masters E.T.; Abbattista A.; Clancy J.S.; Thurm H.; Reisman A.; Peltz G.; Ross Camidge D. | Lung Cancer | 14 | 12 | |
2019 | Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1–2 trial | Shaw A.T.; Solomon B.J.; Chiari R.; Riely G.J.; Besse B.; Soo R.A.; Kao S.; CHIA-CHI LIN ; Bauer T.M.; Clancy J.S.; Thurm H.; Martini J.-F.; Peltz G.; Abbattista A.; Li S.; Ou S.-H.I. | The Lancet Oncology | 234 | 173 | |
2018 | Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study | Solomon B.J.; Besse B.; Bauer T.M.; Felip E.; Soo R.A.; Camidge D.R.; Chiari R.; Bearz A.; CHIA-CHI LIN ; Gadgeel S.M.; Riely G.J.; Tan E.H.; Seto T.; James L.P.; Clancy J.S.; Abbattista A.; Martini J.-F.; Chen J.; Peltz G.; Thurm H.; Ignatius Ou S.-H.; Shaw A.T. | The Lancet Oncology | 572 | 458 | |
2011 | Phase 2 trial of linifanib (ABT-869) in patients with advanced non-small cell lung cancer | Tan E.-H; Goss G.D; Salgia R; Besse B; Gandara D.R; Hanna N.H; CHIH-HSIN YANG ; Thertulien R; Wertheim M; Mazieres J; Hensing T; Lee C; Gupta N; Pradhan R; Qian J; Qin Q; Scappaticci F.A; Ricker J.L; Carlson D.M; Soo R.A. | Journal of Thoracic Oncology | 59 | 57 | |
2020 | Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: Final analysis of the GioTag study | Hochmair M.J.; Morabito A.; Hao D.; Yang C.-T.; Soo R.A.; CHIH-HSIN YANG ; Gucalp R.; Halmos B.; M?rten A.; Cufer T. | Future Oncology | 49 | 45 | |
2017 | A systematic review and meta-analysis of individual patient data on the impact of the BIM deletion polymorphism on treatment outcomes in epidermal growth factor receptor mutant lung cancer | Soh S.X.; Siddiqui F.J.; Allen J.C.; Kim G.W.; Lee J.C.; Yatabe Y.; Soda M.; Mano H.; Soo R.A.; Chin T.-M.; Ebi H.; Yano S.; Matsuo K.; Niu X.; Lu S.; Isobe K.; JIH-HSIANG LEE ; CHIH-HSIN YANG ; Zhao M.; Zhou C.; Lee J.-K.; Lee S.-H.; Lee J.Y.; Ahn M.-J.; Tan T.J.; Tan D.S.; Tan E.-H.; Ong S.T.; Lim W.-T. | Oncotarget | 14 | 12 | |
2020 | Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial | Wu Y.-L.; Cheng Y.; Zhou J.; Lu S.; Zhang Y.; Zhao J.; Kim D.-W.; Soo R.A.; Kim S.-W.; Pan H.; Chen Y.-M.; Chian C.-F.; Liu X.; Tan D.S.W.; Bruns R.; Straub J.; Johne A.; Scheele J.; Park K.; CHIH-HSIN YANG ; Liu Z.; Chen X.; Wang M.; Yu S.; Zhang H.; Fang J.; Li W.; Yang C.-H.; Chang G.-C.; Hsia T.-C.; Yang C.-T.; Wang C.-C.; Cho B.C.; Lee K.H.; Kim Y.-C.; An H.J.; Woo I.S.; Cho J.Y.; Shin S.W.; Lee J.-S.; Kim J.-H.; Yoo S.S.; Kato T.; Shinagawa N.; Tan S.W.D.; Ngo L.S.-M.; Ratnavelu K.; Ahmad A.R.; Liam C.K.; de Marinis F.; Tassone P.; Molla A.I.; Calles Blanco A.; Lazaro Quintela M.E.; Felip Font E.; Dingemans A.-M.; Bui L. | The Lancet Respiratory Medicine | 161 | 128 |